TrometamolCAS# 77-86-1 |
- GW1929
Catalog No.:BCC1611
CAS No.:196808-24-9
- Balaglitazone
Catalog No.:BCC1395
CAS No.:199113-98-9
- Inolitazone
Catalog No.:BCC1652
CAS No.:223132-37-4
- Inolitazone dihydrochloride
Catalog No.:BCC1653
CAS No.:223132-38-5
- Aleglitazar
Catalog No.:BCC1337
CAS No.:475479-34-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 77-86-1 | SDF | Download SDF |
| PubChem ID | 6503 | Appearance | Powder |
| Formula | C4H11NO3 | M.Wt | 121.14 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (412.75 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-amino-2-(hydroxymethyl)propane-1,3-diol | ||
| SMILES | C(C(CO)(CO)N)O | ||
| Standard InChIKey | LENZDBCJOHFCAS-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Commonly used laboratory reagent |
Trometamol Dilution Calculator
Trometamol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 8.2549 mL | 41.2746 mL | 82.5491 mL | 165.0982 mL | 206.3728 mL |
| 5 mM | 1.651 mL | 8.2549 mL | 16.5098 mL | 33.0196 mL | 41.2746 mL |
| 10 mM | 0.8255 mL | 4.1275 mL | 8.2549 mL | 16.5098 mL | 20.6373 mL |
| 50 mM | 0.1651 mL | 0.8255 mL | 1.651 mL | 3.302 mL | 4.1275 mL |
| 100 mM | 0.0825 mL | 0.4127 mL | 0.8255 mL | 1.651 mL | 2.0637 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Trometamol is a proton acceptor used to treat academia.
- Tigogenin
Catalog No.:BCN5327
CAS No.:77-60-1
- Tomatidine
Catalog No.:BCN2773
CAS No.:77-59-8
- Cedrol
Catalog No.:BCN8340
CAS No.:77-53-2
- Ursolic acid
Catalog No.:BCN4327
CAS No.:77-52-1
- Chlorthalidone
Catalog No.:BCC4649
CAS No.:77-36-1
- Gibberellins
Catalog No.:BCN2189
CAS No.:77-06-5
- Garcinone C
Catalog No.:BCN4322
CAS No.:76996-27-5
- Euphroside
Catalog No.:BCN6633
CAS No.:76994-07-5
- Notoginsenoside T5
Catalog No.:BCN3727
CAS No.:769932-34-5
- 15-Methoxypinusolidic acid
Catalog No.:BCN4321
CAS No.:769928-72-5
- TPT-260
Catalog No.:BCC5171
CAS No.:769856-81-7
- Cleomiscosin B
Catalog No.:BCN3898
CAS No.:76985-93-8
- Citric acid
Catalog No.:BCN5374
CAS No.:77-92-9
- Triethyl citrate
Catalog No.:BCC9186
CAS No.:77-93-0
- D-(-)-Quinic acid
Catalog No.:BCN1029
CAS No.:77-95-2
- (+,-)-Octopamine HCl
Catalog No.:BCC4814
CAS No.:770-05-8
- Dehydropachymic acid
Catalog No.:BCN3648
CAS No.:77012-31-8
- Hypocrellin A
Catalog No.:BCN3396
CAS No.:77029-83-5
- Knightinol
Catalog No.:BCN1913
CAS No.:77053-06-6
- Acetylknightinol
Catalog No.:BCN1914
CAS No.:77053-07-7
- Gadobutrol
Catalog No.:BCC4164
CAS No.:770691-21-9
- 6-O-trans-Feruloylcatalpol
Catalog No.:BCN4323
CAS No.:125205-48-3
- 2H-1-Benzopyran-5-ol
Catalog No.:BCN3581
CAS No.:770729-34-5
- MK-801 (Dizocilpine)
Catalog No.:BCC4591
CAS No.:77086-21-6
Comparison of the analgesic efficacy of preoperative/postoperative oral dexketoprofen trometamol in third molar surgery: A randomized clinical trial.[Pubmed:27378000]
J Craniomaxillofac Surg. 2016 Sep;44(9):1350-5.
The aim of this study was to compare the efficacy of preoperative and postoperative dexketoprofen Trometamol for pain control after third molar surgery. Sixty subjects indicated for impacted mandibular third molar surgery were randomly assigned to two groups: preoperative (group 1, n = 30) and postoperative (group 2, n = 30) administration. Group 1 received 25 mg of dexketoprofen Trometamol 30 min before surgery and 1 placebo capsule (same color and size with active drug) immediately after surgery. Group 2 received the placebo capsule 30 min before surgery and 25 mg of dexketoprofen Trometamol immediately after surgery. Pain intensity was assessed using a numeric rating scale (NRS) during the first 8 h. The time of the need for a second dose of dexketoprofen Trometamol, after the first administration, was recorded. The data were analyzed using mixed-model repeated-measures (MMRM), Wilcoxon rank-sum, and Kaplan-Meier analysis. After the 8 h period, no statistically significant difference was observed in the intensity of pain (MMRM, p = 0.41); and no significant difference in the time for a second dose (p = 0.956). In conclusion, preoperative administration of dexketoprofen Trometamol is a reasonable clinical approach that is as effective as conventional postoperative pharmacological treatment, with the advantage of allowing early analgesia before pain develops. (ClinicalTrials.gov: NCT02380001).
Anaphylaxis after intravenous infusion of dexketoprofen trometamol.[Pubmed:27857995]
Turk J Emerg Med. 2016 Sep 29;16(3):132-133.
Dexketoprofen Trometamol (DT), a nonsteroidal anti-inflammatory drug, is a highly water-soluble salt and active enantiomer of rac-ketoprofen. Its parenteral form is commonly used for acute pain management in emergency departments of our country. Side effects such as diarrhea, indigestion, nausea, stomach pain, and vomiting may be seen after the use of DT. Anaphylactic shock (AS) secondary to infusion of DT is very rare and, to our knowledge, it is the first case report describing this side effect. This case report was presented to emphasize that AS may be seen after the use of DT.
[Dexketoprofen trometamol in dorsalgia treatment].[Pubmed:27735904]
Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(9):88-92.
Lower back pain (LBP) remains an important problem due to its high prevalence. LBP is the fifth in frequency among reasons for seeking treatment, and one of the most common among the chronic pain syndromes. Nonsteroidal anti-inflammatory drugs (NSAIDs) are considered to be the <
Double-blind, randomized, double-dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain.[Pubmed:27382251]
Drug Des Devel Ther. 2016 Jun 17;10:1987-93.
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most common type of medication used in the treatment of acute pain. Ketorolac Trometamol (KT) is a nonnarcotic, peripherally acting nonsteroidal anti-inflammatory drug with analgesic effects comparable to certain opioids. OBJECTIVE: The aim of this study was to compare the efficacy of KT and naproxen (NA) in the treatment of acute low back pain (LBP) of moderate-to-severe intensity. PATIENTS AND METHODS: In this 10-day, Phase III, randomized, double-blind, double-dummy, noninferiority trial, participants with acute LBP of moderate-to-severe intensity as determined through a visual analog scale (VAS) were randomly assigned in a 1:1 ratio to receive sublingual KT 10 mg three times daily or oral NA 250 mg three times daily. From the second to the fifth day of treatment, if patient had VAS >40 mm, increased dosage to four times per day was allowed. The primary end point was the reduction in LBP as measured by VAS. We also performed a post hoc superiority analysis. RESULTS: KT was not inferior to NA for the reduction in LBP over 5 days of use as measured by VAS scores (P=0.608 for equality of variance; P=0.321 for equality of means) and by the Roland-Morris Disability Questionnaire (P=0.180 for equality of variance test; P=0.446 for equality of means) using 95% confidence intervals. The percentage of participants with improved pain relief 60 minutes after receiving the first dose was higher in the KT group (24.2%) than in the NA group (6.5%; P=0.049). The most common adverse effects were heartburn, nausea, and vomiting. CONCLUSION: KT is not inferior in efficacy and delivers faster pain relief than NA.
